Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645638 | 0.79 | ALDH1A1 (0.44) | ALDH1A1ALPLLMNAKDM4EGAA | |
| SCHEMBL2113726 | 0.79 | MEN1 (0.45) | ALDH1A1ALPLKDM4EGAA | |
| SCHEMBL17627048 | 0.79 | ALDH1A1 (0.44) | ALDH1A1ALPLLMNAKDM4EGAA | |
| SCHEMBL16479224 | 0.76 | ALOX15 (0.51) | ALDH1A1ALPLLMNANR1H3HTT | |
| SCHEMBL30475298 | 0.76 | ALDH1A1 (0.41) | ALDH1A1ALPLGAA | |
| SCHEMBL3051213 | 0.76 | ALDH1A1 (0.41) | ALDH1A1ALPLGAA | |
| SCHEMBL14858215 | 0.74 | CCNA2 (0.42) | ALDH1A1ALPL | |
| SCHEMBL3996867 | 0.74 | ALDH1A1 (0.45) | ALDH1A1ALPLESR1PIM3HIPK4 | |
| SCHEMBL31727467 | 0.74 | ALDH1A1 (0.45) | ALDH1A1ALPLESR1PIM3HIPK4 | |
| SCHEMBL20582184 | 0.72 | ALDH1A1 (0.38) | ALDH1A1ALPLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4081526-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2021134004-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRODINGER, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021134004-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRODINGER, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2288611-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8404694-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2288611-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009117157-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | ALDH1A1 2417/4885ALPL 1450/4885ESR1 995/4885 |
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | ALDH1A1 2417/4885ALPL 1450/4885ESR1 995/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | ALDH1A1 2190/4885ALPL 3272/4885ESR1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.